Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?

References

• Libby PL: The forgotten majority. Unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46, 1225–1228 (2005).
   Google Scholar
• Fruchart J-C, Sacks F, Hermans MP et al.: Executive statement: the Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidemic patients. A condensed position paper by the Residual Risk Reduction Initiative (R3i). Diab. Vasc. Dis. Res. 5, 319–335 (2008).
   Google Scholar
• Fruchart J-C, Sacks F, Hermans MP et al.; for the Residual Risk Reduction Initiative: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(Suppl.), 1–34 (2008). Extensive, in-depth review provides not only a definition of residual vascular risk focusing on atherogenic dyslipidemia, the current scientific evidence and a call-toaction to reduce such unaddressed need in high-risk patients.
   Google Scholar
• Jones PH: Expert perspective: reducing cardiovascular risk in metabolic syndrome and Type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am. J. Cardiol. 102, 41L–47L (2008).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
   Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al.; American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al.; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG): European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Executive summary. Eur. Heart J. 28, 2375–2414 (2007).
   Google Scholar
• Ryden L, Standl E, Bartnik M et al.: Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28, 88–136 (2007).
   Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al.: Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 51, 1512–1524 (2008). This consensus from two major cardiology and diabetes scientific associations provides a summary of optimal LDL management and targets, including the rationale and updated management values for LDL-C, non-HDL-C and apoB in high-risk patients.
   Google Scholar
• American Diabetes Association: Clinical practice recommendations. Diabetes Care 33, S1–S100 (2010).
   Google Scholar
• Dodson PM: Diabetes and the Eye. In: Diabetic Retinopathy. Dodson PM (Ed.). Oxford University Press, Oxford, UK (2009).
   Google Scholar
• Tesfaye S, Chaturvedi N, Eaton SE et al.; EURODIAB Prospective Complications Study Group: Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352, 341–350 (2005).
   Google Scholar
• Hermans MP: Diabetic macro- and microvascular disease in Type 2 diabetes. Diabetes Vasc. Dis. Res. 4, S7–S11 (2007).
   Google Scholar
• Hermans MP, Ahn SA, Rousseau MF: Erectile dysfunction, microangiopathy and UKPDS risk in Type 2 diabetes. Diabetes Metab. 35, 484–489 (2009).
   Google Scholar
• Rajamani K, Colman PG, Li LP et al.; FIELD study investigators: Effect of fenofibrate on amputation events in people with Type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373, 1780–1788 (2009). Describes the marked beneficial effects of fenofibrate to prevent nontraumatic lower-limb amputations in Type 2 diabetes mellitus patients.
   Google Scholar
• Chew EY, Ambrosius WT, Howard LT et al.; ACCORD Study Group: Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am. J. Cardiol. 99(12A), 103I–111I (2007).
   Google Scholar
• Friedewald VE Jr, Ballantyne CM, Davidson MH, Guyton JR, Roberts WC: The editor’s roundtable: lipid management beyond statins – reducing residual cardiovascular risk. Am. J. Cardiol. 102, 559–567 (2008). This roundtable covers in a medium-size format most of the current issues on lipid-related residual vascular risk in a poststatin paradigm.
   Google Scholar
• Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P: New risk factors for atherosclerosis and patient risk assessment. Circulation 109(23 Suppl. 1), III15–III19 (2004).
   Google Scholar
• Assmann G, Cullen P, Fruchart JC et al.: International Task Force for Prevention of Coronary Heart Disease: implications of emerging risk factors for therapeutic intervention. Nutr. Metab. Cardiovasc. Dis. 15, 373–381 (2005).
   Google Scholar
• Yusuf S, Hawken S, Ôunpuu S et al.; on behalf of the INTERHEART investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364, 937–952 (2004).
   Google Scholar
• Brown G, Albers JJ, Fisher LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323, 1289–1298 (1990).
   Google Scholar
• HPS Collaborative Group: MRC/BHF Heart Protection Study of Cholesterol-Lowering with Simvastatin in 5,963 People with Diabetes: a randomised placebo-controlled trial. Lancet 361, 2005–2016 (2003).
   Google Scholar
• Sacks FM, Tonkin AM, Shepherd J et al.: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102, 1893–1900 (2000).
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al.; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685–696 (2004).
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).
   Google Scholar
• Shepherd J, Barter P, Carmena R et al.; Treating to New Targets Investigators: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 29, 1220–1226 (2006).
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al.; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reative protein. N. Engl. J. Med. 359, 2195–2207 (2008).
   Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234 (1998).
   Google Scholar
• Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Type 2 diabetes as a ‘coronary heart disease equivalent’. An 18 year prospective population-based study in Finnish subjects. Diabetes Care 28, 2901–2907 (2005).
   Google Scholar
• Buyken AE, von Eckardstein A, Schulte H, Cullen P, Assmann G: Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur. J. Cardiovasc. Prev. Rehabil. 14, 230–236 (2007).
   Google Scholar
• Mazzone T, Chait A, Plutzky J: Cardiovascular disease risk in Type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371, 1800–1809 (2008).
   Google Scholar
• Schramm TK, Gislason GH, Køber L et al.: Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117, 1945–1954 (2008).
   Google Scholar
• Ferrieres J, Tocque-Le Gousse E, Fabry C, Hermans MP; on behalf of the French CEPHEUS investigators: Assessment of lipid-lowering treatment in France. Arch. Cardiovasc. Dis. 101, 557–563 (2008).
   Google Scholar
• Hermans MP, Castro Cabezas M, Strandberg T et al.: Centralized pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr. Med. Res. Opin. 26, 445–454 (2010).
   Google Scholar
• Manninen V, Tenkanen L, Koskinen P et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 37–45 (1992).
   Google Scholar
• Davignon J, Cohn JS: Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 124(Suppl.) S57–S64 (1996).
   Google Scholar
• Brites FD, Bonavita CD, De Geitere C et al.: Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 152, 181–192 (2000). Examines how hypertriglyceridemia affects major aspects of HDL metabolism involved in reverse cholesterol transport in hypertriglyceridemic patients.
   Google Scholar
• Fruchart JC, Duriez P: HDL and triglyceride as therapeutic targets. Curr. Opin. Lipidol. 13, 605–616 (2002).
   Google Scholar
• Kathiresan S, Otvos JD, Sullivan LM et al.: Increased small low-density lipoprotein particle number. A prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113, 20–29 (2006).
   Google Scholar
• Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH: Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am. J. Cardiol. 100, 1499–1501 (2007).
   Google Scholar
• Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298, 309–316 (2007).
   Google Scholar
• Barter P, Gotto AM, LaRosa JC et al.; Treating to New Targets Investigators: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357, 1301–1310 (2007).
   Google Scholar
• Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE-IT TIMI 22 Investigators: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J. Am. Coll. Cardiol. 51, 724–730 (2008).
   Google Scholar
• Rana JS, Visser ME, Arsenault BJ et al.: Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Int. J. Cardiol. 143(3), 399–404 (2010).
   Google Scholar
• Assmann G, Cullen P, Schulte H: Non-LDL-related dyslipidemia and coronary risk: a case-control study. Diab. Vasc. Dis. Res. 7, 204–212 (2010).
   Google Scholar
• Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P: Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis systematic review and meta-regression analysis. Atherosclerosis 212(1), 9–15(2010).
   Google Scholar
• Sarwar N, Sandhu MS, Ricketts SL et al.: Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375, 1634–1639 (2010).
   Google Scholar
• Garvey WT, Kwon S, Zheng D et al.: Effects of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52, 453–462 (2003).
   Google Scholar
• Adiels M, Olofsson S-O, Taskinen M-R, Borén J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 1225–1236 (2008).
   Google Scholar
• Lteif A, Mather K: Insulin resistance, metabolic syndrome and vascular diseases: update and mechanistic linkages. Can. J. Cardiol. 20(Suppl. B), 66B–76B (2004).
   Google Scholar
• Assmann G, Schulte H, Seedorf U: Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int. J. Obes. (Lond.) 32(Suppl. 2), S11–S16 (2008).
   Google Scholar
• Bonora E, Targher G, Formentini G et al.: The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet. Med. 21, 52–58 (2004).
   Google Scholar
• Bruno G, Merletti F, Biggeri A et al.: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in Type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27, 2689–2694 (2004).
   Google Scholar
• Metascreen Writing Committee: The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes. Results from Metascreen, a multicenter diabetes clinicbased survey. Diabetes Care 29, 2701–2707 (2006).
   Google Scholar
• Cull CA, Jensen CC, Retnakaran R, Holman RR: Impact of the metabolic syndrome on macrovascular and microvascular outcomes in Type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 116, 2119–2126 (2007).
   Google Scholar
• Sadikot SM, Misra A: The metabolic syndrome: an exercise in utility or futility? Diabetes Metab. Syndr. Clin. Res. Rev. 1, 3–21 (2007).
   Google Scholar
• Alberti KG, Eckel RH, Grundy SM et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009).
   Google Scholar
• Hermans MP, Ahn SA, Amoussou-Guenou KD, Rousseau MF: Impact of metabolic syndrome on microvascular complications in Type 2 diabetes. Diab. Metab. Syndr. 4(3), 150–154 (2010).
   Google Scholar
• Sadikot S, Hermans MP: Here we go again … The metabolic syndrome revisited! Diab. Metab. Syndr. 4, 111–120 (2010).
   Google Scholar
• Davis RA: Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim. Biophys. Acta 1440, 1–31 (1999).
   Google Scholar
• Blasiole DA, Davis RA, Attie AD: The physiological and molecular regulation of lipoprotein assembly and secretion. Mol. Biosyst. 3, 608–619 (2007). Extensively covers the regulation and requisites of apoB-containing lipoprotein production by the liver.
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972).
   Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358, 2026–2033 (2001).
   Google Scholar
• Lu W, Resnick HE, Jablonski KA et al.: Non-HDL cholesterol as a predictor of cardiovascular disease in Type 2 diabetes: The Strong Heart Study. Diab. Care 26, 16–23 (2003).
   Google Scholar
• Denke MA: Weighing in before the fight. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 112, 3368–3370 (2005).
   Google Scholar
• Pischon T, Girman GJ, Sacks FM, Rifai N, Stampfer NJ, Rimm EB: Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men, Circulation 112, 3375–3383 (2005).
   Google Scholar
• Sniderman AD: Apolipoprotein B versus non-high-density lipoprotein cholesterol. And the winner is… Circulation 112, 3366–3367 (2005).
   Google Scholar
• Ahmad J, Khan AR, Ahmed F, Siddiqui S: Non-HDL cholesterol versus apolipoprotein B in the identification of dyslipidemic phenotypes associated with cardiovascular risk in Type 2 diabetic dyslipoproteinemia. Diab. Metab. Syndr. 1, 29–36 (2007).
   Google Scholar
• Hermans MP, Ahn SA, Rousseau MF: The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers. Diab. Metab. Syndr. 1, 23–28 (2007).
   Google Scholar
• Sulkes D, Brown BG, Krauss RM, Segrest JP, Sniderman AD, Roberts WC: The editor’s roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk. Am. J. Cardiol. 101, 828–842 (2008). This roundtable covers contemporary issues on practical lipid measurement, dyslipidemia screening and the use of lipoprotein markers to assess and manage cardiovascular risk.
   Google Scholar
• Rosenson RS: Management of non-high-density lipoprotein abnormalities. Atherosclerosis 207, 328–335 (2009).
   Google Scholar
• Kawakami A, Osaka M, Tani M et al.: Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 118, 731–742 (2008). containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler. Thromb. Vasc. Biol. 30, 239–245 (2010). Provides a concise description of the complex link between apoCIII-carrying triglyceride-rich lipoproteins and non-LDL-related atherosclerotic processes.
   Google Scholar
• Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM: Metabolism of very-low-density lipoprotein and low-density lipoprotein
   Google Scholar
• Zheng C, Khoo C, Furtado J, Sacks FM: Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 121, 1722–1734 (2010).
   Google Scholar
• Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ: Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am. J. Cardiol. 101, 497–501 (2008).
   Google Scholar
• da Luz PL, Favarato D, Faria-Neto JR Jr, Lemos P, Chagas AC: High ratio of triglycerides to HDL-Cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 63, 427–432 (2008).
   Google Scholar
• Bittner V, Johnson BD, Zineh I et al.: The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women’s Ischemia Syndrome Evaluation (WISE). Am. Heart J. 157, 548–555 (2009).
   Google Scholar
• Cordero A, Andrés E, Ordoñez B et al.; MESYAS (Metabolic Syndrome Active Subjects) Study Investigators: usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. Am. J. Cardiol. 104, 1393–1397 (2009).
   Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al.; ACCORD Study Group: Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010). Confirms the extent of residual vascular risk related to atherogenic dyslipidemia in Type 2 diabetes mellitus patients despite statin therapy, and the substantial decrease in events achieved by combination therapy with fenofibrate in this subset of patients.
   Google Scholar
• Fruchart J-C, Sacks FM, Hermans MP: Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R3i). Curr. Med. Res. Opin. 26, 1793–1797 (2010).
   Google Scholar
• Sumner AE, Vega GL, Genovese DJ, Finley KB, Bergman RN, Boston RC: Normal triglyceride levels despite insulin resistance in African Americans: role of lipoprotein lipase. Metabolism 54, 902–909 (2005).
   Google Scholar
• Dehout F, Haumont S, Gaham N, Amoussou-Guenou KD, Hermans MP: Metabolic syndrome in Bantu subjects with Type 2 diabetes from sub-Saharan extraction: prevalence, gender differences and HOMAhyperbolic product. Diab. Metab. Syndr. 2, 5–11 (2008).
   Google Scholar
• Munoko TH, Hermans MP: Phenotypic characterization of first generation Maghrebian migrants with Type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort. Diab. Met. Syndr. 2, 115–124 (2008).
   Google Scholar
• Paramsothy P, Knopp R, Bertoni AG, Tsai MY, Rue T, Heckbert SR: Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis (MESA). Metabolism 58, 212–219 (2009).
   Google Scholar
• Dobiásová M, Frohlich J: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoBlipoprotein-depleted plasma (FERhdl). Clin. Biochem. 34, 583–588 (2001).
   Google Scholar
• Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M: Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism 59, 299–304 (2010).
   Google Scholar
• Katcher HI, Hill AM, Lanford JL, Yoo JS, Kris-Etherton PM: Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-Cholesterol. Endocrinol. Metab. Clin. North Am. 38, 45–78 (2009).
   Google Scholar
• Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group: The UKPDS Risk Engine: a model for the risk of coronary heart disease in Type 2 diabetes. Clin. Science 101, 671–679 (2001).
   Google Scholar
• Assmann G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 105, 310–315 (2002).
   Google Scholar
• Kothari V, Stevens RJ, Adler AI et al.: UKPDS 60: risk of stroke in Type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33, 1776–1781 (2002).
   Google Scholar
• Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR: UKPDS 66: risk factors for myocardial infarction case fatality and stroke case fatality in Type 2 diabetes. Diabetes Care 27, 201–207 (2004).
   Google Scholar
• Coleman RL, Stevens RJ, Retnakaran R, Holman RR: Framingham, SCORE and DECODE do not provide reliable cardiovascular risk estimates in Type 2 diabetes. Diabetes Care 30, 1292–1293 (2007).
   Google Scholar
• Eichler K, Puhan MA, Steurer J, Bachmann LM: Prediction of first coronary events with the Framingham score: a systematic review. Am. Heart J. 153, 722–731 (2007).
   Google Scholar
• Wilson PW: Risk scores for prediction of coronary heart disease: an update. Endocrinol. Metab. Clin. N. Am. 38, 33–44 (2009).
   Google Scholar
• Hermans MP, Ahn SA, Rousseau MF: Cardiometabolic phenotype and UKPDS risk in male Type 2 diabetic patients with obstructive sleep apnoea syndrome. Diabetes Metab. Syndr. 3, 50–54 (2009).
   Google Scholar
• Assmann G, Schulte H, Cullen P, Seedorf U: Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur. J. Clin. Invest. 37, 925–932 (2007).
   Google Scholar
• Carey VJ, Bishop L, Laranjo N, Harschfield BJ, Kwiat C, Sacks FM: Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am. J. Cardiol. 106, 757–763 (2010). Confirms the epidemiological concept of macrovascular residual vascular risk related to atherogenic dyslipidemia, including the synergism between triglyceride and low HDL-C, which persists even when LDL-C is set at target.
   Google Scholar
• Taylor AJ, Villines TC, Stanek E et al.: Extended-release niacin or ezetimibe and carotid intima–media thickness. N. Engl. J. Med. 361, 2113–2122 (2009).
   Google Scholar
• Villines TC, Stanek EJ, Devine PJ et al.: The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J. Am. Coll. Cardiol. 55, 2721–2726 (2010).
   Google Scholar
• Cushman WC, Grimm RH, Cutler JA; for the ACCORD study group: Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am. J. Cardiol. 99(12A), 44I–55I (2007).
   Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP et al.: Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).
   Google Scholar
• ACCORD Study Group; ACCORD Eye Study Group, Chew EY et al.: Effects of medical therapies on retinopathy progression in Type 2 diabetes. N. Engl. J. Med. 363233–244 (2010). Confirms the extent of microvascular residual vascular risk in Type 2 diabetes mellitus patients, and the substantial decrease in microvascular retinopathy events achieved by combination therapy with fenofibrate.
   Google Scholar
• The UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. UKPDS 33. Lancet 837–853 (1998).
   Google Scholar
• UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS 38. BMJ 317, 703–713 (1998).
   Google Scholar
• Schrier RW, Estacio RO, Esler A et al.: Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 61, 1086–1097 (2002).
   Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348, 383–393 (2003).
   Google Scholar
• Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR: Additive effects of glycaemia and blood pressure exposure on risk of complications in Type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49, 1761–1769 (2006).
   Google Scholar
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).
   Google Scholar
• Patel A, ADVANCE Collaborative Group; MacMahon S et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829–840 (2007).
   Google Scholar
• Fioretto P, Dodson PM, Ziegler D, Rosenson RS: Residual microvascular risk in diabetes: unmet needs and future directions. Nat. Rev. Endocrinol. 6, 19–25 (2010). Reviews the evidence and epidemiological association with dyslipidemia, including atherogenic dyslipidemia with regard to residual vascular risk of microangiopathy in hyperglycemic states.
   Google Scholar
• Dorman TL, Carter RD, Bron AJ, Turner RC, Mann JI: Low density lipoprotein cholesterol: an association with the severity of diabetic retinopathy. Diabetologia 22, 167–170 (1982).
   Google Scholar
• Klein BE, Moss SE, Klein R, Surawicz TS: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98, 1261–1265 (1991).
   Google Scholar
• Chew EY, Klein ML, Ferris FL III et al.: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Editors Report 22. Arch. Ophthalmol. 114, 1079–1084 (1996).
   Google Scholar
• Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC: The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid-lowering therapy? Eye (Lond.) 16, 689–693 (2002).
   Google Scholar
• Misra A, Kumar S, Kishore Vikram A, Kumar A: The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am. J. Cardiovasc. Drugs 3, 325–338 (2003).
   Google Scholar
• Lyons TJ, Jenkins AJ, Zheng D et al.: Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest. Ophthalmol. Vis. Sci. 45, 910–918 (2004).
   Google Scholar
• Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA: A prospective study of serum lipids and risk of diabetic macular edema in Type 1 diabetes. Diabetes 53, 2883–2892 (2004).
   Google Scholar
• Ucgun NI, Yildirim Z, Kiliç N, Gürsel E: The importance of serum lipids in exudative diabetic macular edema in Type 2 diabetic patients. Ann. NY Acad. Sci. 100, 213–217 (2007).
   Google Scholar
• Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005).
   Google Scholar
• Keech AC, Mitchell P, Summanen PA et al.: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370, 1687–1697 (2007).
   Google Scholar
• Dodson PM: Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering? Pract. Diab. Int. 25, 76–79 (2008).
   Google Scholar
• Scott R, O’Brien R, Fulcher G et al.; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators: The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with Type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 32, 493–498 (2009).
   Google Scholar
• Hermans MP: Impact of fenofibrate on Type 2 diabetes patients with features of the metabolic syndrome: subgroup analysis from FIELD. Curr. Cardiol. Rev. 6, 112–118 (2010).
   Google Scholar
• Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357, 905–910 (2001).
   Google Scholar
• Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485–493 (2005).
   Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088–2093 (1998).
   Google Scholar
• Fruchart JC: Peroxisome proliferator-activated receptor-a (PPARa): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205, 1–8 (2009). Provides a concise overview of PPAR-ainvolvement and the potential benefits of their modulation in cardiometabolic states.
   Google Scholar
• Jun M, Foote C, Lv J et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375, 1875–1884 (2010). Extensive and up-to-date meta-analysis confirms the beneficial role of fibrates for cardiac protection, in particular in high-risk patients.
   Google Scholar
• Volek JS, Fernandez ML, Feinman RD, Phinney SD: Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog. Lipid Res. 47, 307–318 (2008).
   Google Scholar
• Ducobu J, Scheen A, Van Gaal L, Velkeniers B, Hermans M: Belgian Expert opinion: how to reduce the residual risk in atherogenic dyslipidemic patients: place of fibrates. Acta Cardiol. 63, 235–248 (2008).
   Google Scholar
• Chapman MJ, Redfern JS, McGovern ME, Giral P: Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther. 126, 314–345 (2010).
   Google Scholar
• Rosenson RS, Davidson MH, Pourfarzib R: Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis DOI:10.1016/j. atherosclerosis.2010.03.038 (2010) (Epub ahead of print). A short review of the evidence for current management opportunities to deal with the various aspects of LDL hypercholesterolemia, including particle size, apoB and non-HDL-C.
   Google Scholar